Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study

The purpose of this study is to provide Defibrotide to patients diagnosed with VOD. Defibrotide is no longer available though the Emergency Use IND mechanism (also known as compassionate use, or single patient named use). This protocol is the only mechanism by which Defibrotide can be made available to patients in the U.S.

Stanford is now accepting new patients for this trial. Please contact Physician Referrals at 6507230822 for more information.



  • drug : Defibrotide

Phase: Phase 3


Ages Eligible For Study:

N/A - N/A

Inclusion Criteria

Entry criteria include the following: 1. Clinical diagnosis of VOD, made by Baltimore Criteria, Modified Seattle Criteria, or biopsy proven: 1.1 Baltimore Criteria- Bilirubin ?2 mg/dL and at least 2 of the following clinical findings: - Ascites (radiographic or physical exam) - Weight gain of ?5% compared to the day of conditioning-- if this value is not available, the weight on the date of admission to the SCT unit may be used) - Hepatomegaly; increased over baseline. 1.2 Modified Seattle Criteria: At least two of the following - Bilirubin ?2 mg/dL - Ascites (radiographic or physical exam) and/or weight gain ?5% above baseline weight (defined as weight on the first day of conditioning- if this value is not available, the weight on the date of admission to the SCT unit may be used) - hepatomegaly increased over baseline 1.3 Patients that do not meet the Baltimore Criteria or Modified Seattle Criteria and have biopsy proven VOD are eligible. 2. Patient must also provide written informed consent.

External Links

Explore related trials

Contact information

Primary Contact:

Physician Referrals 6507230822

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: